Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $13.63 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others... Read more
Sell if holding. Analyst target reached at $13.63 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: Death cross but MACD improving, RSI 50. Score 4.2/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Dr. Reddy's Laboratories Ltd
Latest news
- Dr. Reddy's Laboratories Ltd (RDY) Releases Q4 2026 Earnings: Revenue and Profits Plunge, Margins Compressed - Quiver Qu — Quiver Quantitative negative
- Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss - GuruFocus — GuruFocus negative
- Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY) - Seeking Alpha — Seeking Alpha positive
- Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS — AD HOC NEWS neutral
- Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday - MarketBeat — MarketBeat neutral
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -11.6% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $13.63 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: Death cross but MACD improving, RSI 50. Prior stop was $12.89. Score 4.2/10, moderate confidence.
Take-profit target: $13.92 (+2.1% upside). Prior stop was $12.89. Stop-loss: $12.89.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Consecutive earnings misses (2).
Dr. Reddy's Laboratories Ltd trades at a P/E of 25.9 (forward 19.9). TrendMatrix value score: 5.8/10. Verdict: Sell.
44 analysts cover RDY with a consensus score of 3.3/5. Average price target: $14.
What does Dr. Reddy's Laboratories Ltd do?Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company...
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.